Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Taiho Oncology, Inc.
Seagen Inc.
Eli Lilly and Company
Alliance for Clinical Trials in Oncology
University of Southern California
National Cancer Institute (NCI)
University Hospital, Geneva